{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:12:42Z","timestamp":1791051162284,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/ejhg.2012.261","type":"journal-article","created":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T06:23:07Z","timestamp":1354083787000},"page":"769-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2"],"prefix":"10.1038","volume":"21","author":[{"name":"on behalf of the NF2 Multidisciplinary Clinics HUGTiP-ICO-IMPPC","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Castellanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ares","family":"Solanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Bielsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxi","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hostalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pepe","family":"Prades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Roca-Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,28]]},"reference":[{"key":"BFejhg2012261_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"19","author":"D Evans","year":"2009","unstructured":"Evans D : Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 19: 16.","journal-title":"Orphanet J Rare Dis"},{"key":"BFejhg2012261_CR2","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1101\/gad.1335605","volume":"19","author":"AI McClatchey","year":"2005","unstructured":"McClatchey AI, Giovannini M : Membrane organization and tumorigenesis\u2014the NF2 tumor suppressor, Merlin. Genes Dev 2005; 19: 2265\u20132277.","journal-title":"Genes Dev"},{"key":"BFejhg2012261_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791\u2013800.","journal-title":"Cell"},{"key":"BFejhg2012261_CR4","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA et al: Neurofibromatosis type 2. Lancet 2009; 373: 1974\u20131986.","journal-title":"Lancet"},{"key":"BFejhg2012261_CR5","first-page":"727","volume":"63","author":"DGR Evans","year":"1998","unstructured":"Evans DGR, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T : Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 Neurofibromatosis. Am J Human Genet 1998; 63: 727\u2013736.","journal-title":"Am J Human Genet"},{"key":"BFejhg2012261_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/jmg.40.2.109","volume":"40","author":"L Kluwe","year":"2003","unstructured":"Kluwe L, Mautner V, Heinrich B et al: Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003; 40: 109\u2013114.","journal-title":"J Med Genet"},{"key":"BFejhg2012261_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1399-0004.2011.01816.x","volume":"82","author":"DG Evans","year":"2011","unstructured":"Evans DG, Raymond FL, Barwell JG, Halliday D : Genetic testing and screening of individuals at risk of NF2. Clin Genet 2011; 82: 416\u2013424.","journal-title":"Clin Genet"},{"key":"BFejhg2012261_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/humu.20393","volume":"28","author":"I Ahronowitz","year":"2007","unstructured":"Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP : Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 2007; 28: 1\u201312.","journal-title":"Hum Mutat"},{"key":"BFejhg2012261_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/humu.20317","volume":"27","author":"ME Baser","year":"2006","unstructured":"Baser ME : The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006; 27: 297\u2013306.","journal-title":"Hum Mutat"},{"key":"BFejhg2012261_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/gcc.20876","volume":"50","author":"JR Ellis","year":"2011","unstructured":"Ellis JR, Heinrich B, Mautner VF, Kluwe L : Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions. Genes Chromosomes Cancer 2011; 50: 571\u2013584.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFejhg2012261_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1096-8628(19980518)77:3<228::AID-AJMG8>3.0.CO;2-L","volume":"77","author":"L Kluwe","year":"1998","unstructured":"Kluwe L, MacCollin M, Tatagiba M et al: Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998; 77: 228\u2013233.","journal-title":"Am J Med Genet"},{"key":"BFejhg2012261_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/gcc.2870120206","volume":"12","author":"P Merel","year":"1995","unstructured":"Merel P, Hoang-Xuan K, Sanson M et al: Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995; 12: 117\u2013127.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFejhg2012261_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","volume":"77","author":"SK Selvanathan","year":"2010","unstructured":"Selvanathan SK, Shenton A, Ferner R et al: Further genotype--phenotype correlations in neurofibromatosis 2. Clin Genet 2010; 77: 163\u2013170.","journal-title":"Clin Genet"},{"key":"BFejhg2012261_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/humu.21260","volume":"31","author":"DN Cooper","year":"2010","unstructured":"Cooper DN, Chen J-M, Ball EV et al: Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum Mutat 2010; 31: 631\u2013655.","journal-title":"Hum Mutat"},{"key":"BFejhg2012261_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/hmg\/7.3.393","volume":"7","author":"A De Klein","year":"1998","unstructured":"De Klein A, Riegman PHJ, Bijlsma EK et al: A G\u2192A transition creates a branch point sequence and activation of a cryptic exon, resulting in the hereditary disorder Neurofibromatosis 2. Hum Mol Genet 1998; 7: 393\u2013398.","journal-title":"Hum Mol Genet"},{"key":"BFejhg2012261_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1749-6632.2010.05836.x","volume":"1214","author":"A Aartsma-Rus","year":"2010","unstructured":"Aartsma-Rus A, den Dunnen JT, van Ommen GJ : New insights in gene-derived therapy: the example of Duchenne muscular dystrophy. Ann N Y Acad Sci 2010; 1214: 199\u2013212.","journal-title":"Ann N Y Acad Sci"},{"key":"BFejhg2012261_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.cell.2012.02.014","volume":"148","author":"P Spitali","year":"2012","unstructured":"Spitali P, Aartsma-Rus A : Splice modulating therapies for human disease. Cell 2012; 148: 1085\u20131088.","journal-title":"Cell"},{"key":"BFejhg2012261_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D : Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7: 187\u2013195.","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"BFejhg2012261_CR19","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.97.17.9591","volume":"97","author":"G Lacerra","year":"2000","unstructured":"Lacerra G, Sierakowska H, Carestia C et al: Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci 2000; 97: 9591\u20139596.","journal-title":"Proc Natl Acad Sci"},{"key":"BFejhg2012261_CR20","doi-asserted-by":"publisher","first-page":"36193","DOI":"10.1074\/jbc.274.51.36193","volume":"274","author":"KJ Friedman","year":"1999","unstructured":"Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R : Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 1999; 274: 36193\u201336199.","journal-title":"J Biol Chem"},{"key":"BFejhg2012261_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/humu.20933","volume":"30","author":"E Pros","year":"2009","unstructured":"Pros E, Fern\u00e1ndez-Rodr\u00edguez J, Canet B et al: Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat 2009; 30: 454\u2013462.","journal-title":"Hum Mutat"},{"key":"BFejhg2012261_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"D Evans","year":"2005","unstructured":"Evans D, Baser M, O'Reilly B et al: Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005; 19: 5\u201312.","journal-title":"Br J Neurosurg"},{"key":"BFejhg2012261_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","volume":"15","author":"LM Messiaen","year":"2000","unstructured":"Messiaen LM, Callens T, Mortier G et al: Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15: 541\u2013555.","journal-title":"Hum Mutat"},{"key":"BFejhg2012261_CR24","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski Z, Kole R : Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90: 8673\u20138677.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFejhg2012261_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1101\/gad.1054603","volume":"17","author":"D Lallemand","year":"2003","unstructured":"Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI : NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003; 17: 1090\u20131100.","journal-title":"Genes Dev"},{"key":"BFejhg2012261_CR26","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1128\/MCB.22.4.1150-1157.2002","volume":"22","author":"AM Bashour","year":"2002","unstructured":"Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N : The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol 2002; 22: 1150\u20131157.","journal-title":"Mol Cell Biol"},{"key":"BFejhg2012261_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P : Merlin\/Neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007; 67: 520\u2013527.","journal-title":"Cancer Res"},{"key":"BFejhg2012261_CR28","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/sj.onc.1202141","volume":"17","author":"PD Pelton","year":"1998","unstructured":"Pelton PD, Sherman LS, Rizvi TA et al: Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998; 17: 2195\u20132209.","journal-title":"Oncogene"},{"key":"BFejhg2012261_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/molecules14031304","volume":"14","author":"JD Moulton","year":"2009","unstructured":"Moulton JD, Jiang S : Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 2009; 14: 1304\u20131323.","journal-title":"Molecules"},{"key":"BFejhg2012261_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd3459","volume":"10","author":"F Muntoni","year":"2011","unstructured":"Muntoni F, Wood MJ : Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 2011; 10: 621\u2013637.","journal-title":"Nat Rev Drug Discov"},{"key":"BFejhg2012261_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3233\/JAD-2011-111517","volume":"28","author":"MA Erickson","year":"2012","unstructured":"Erickson MA, Niehoff ML, Farr SA et al: Peripheral administration of antisense oligonucleotides targeting the amyloid-beta protein precursor reverses AbetaPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 2012; 28: 951\u2013960.","journal-title":"J Alzheimers Dis"},{"key":"BFejhg2012261_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F et al: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123\u2013126.","journal-title":"Nature"},{"key":"BFejhg2012261_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al: Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74: 1031\u20131044.","journal-title":"Neuron"},{"key":"BFejhg2012261_CR34","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM et al: Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3: 72ra18.","journal-title":"Sci Transl Med"}],"updated-by":[{"DOI":"10.1038\/ejhg.2013.224","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T00:00:00Z","timestamp":1386806400000}}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ejhg2012261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg2012261","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg2012261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:07:00Z","timestamp":1684415220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ejhg2012261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,28]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFejhg2012261"],"URL":"https:\/\/doi.org\/10.1038\/ejhg.2012.261","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,28]]},"assertion":[{"value":"25 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}